What is it about?
An equivalently high SVR rate was observed in CHC patients with either past or active HCC compared to non-HCC patients who received DAAs. Patients with active HCC had more safety concerns during DAAs treatment.However, the safety concerns did not compromise treatment efficacy.
Featured Image
Read the Original
This page is a summary of: Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study, BMJ Open, May 2019, BMJ,
DOI: 10.1136/bmjopen-2018-026703.
You can read the full text:
Contributors
The following have contributed to this page
